Skip to main content

Table 1 Basic characteristics of the randomized controlled trials included

From: Neoadjuvant chemoradiation therapy for resectable esophago-gastric adenocarcinoma: a meta-analysis of randomized clinical trials

Study and year Country Cancer position R0 resection Down-staging pCR of CRT Journal publication
Walsh, [27] Ireland Stomach NM 13(25.0%) NEJM
Esophagus
Urba, [30] USA Stomach 90(92.8%) 9(24.3%) JCO
Esophagus
TROG, [31] Australia Esophagus 179(69.9%) NM Lancet Oncol
CALGB9781, [28] USA Stomach NM 10(40.0%) JCO
Esophagus
Stahl, [33] German Stomach 84(70.6%) 7(11.7%) JCO
Burmeister, [32] Australia Stomach 62(82.7%) 5(12.8%) EJC
Esophagus
CROSS, [29] Netherlands Stomach 259(70.8%) 28(23.1%) NEJM
Esophagus
  1. Note: pCR: pathological complete response; CRT: preoperative chemoradiation therapy; CT: preoperative chemotherapy; NM: not mentioned.